Protect yourself
By the time you read this lakhs of chickens will have died of avian flu. Some will have died naturally. Others will have been beaten to death or strangled. How many do you think will be buried or burnt? Very few. Most of them will land on your plate, sold at reduced prices by the poultries. So what, you say. The newspapers have repeatedly told you that bird flu makes no difference to the quality of chicken you eat and, as long as you cook it, you will come to no harm.
This is utter rubbish and it is being doled out by two interested parties: the poultry industry themselves, so that they do not go completely bankrupt and you continue to buy the diseased dead birds. The second is the government itself: the Animal Husbandry Ministry, which is solely invented to see that India has more poultries, more slaughterhouses. The more animals are eaten, the more successful the Ministry is. Their mandate is NOT sick people. Their mandate is to see that people keep buying chicke
Search jobs 20-Jan-2021 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Mergers & Acquisitions
20.01.2021 / 07:00
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (
Relief ), a biopharmaceutical company with its lead compound RLF-100
TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH (
Edesa Biotech to Join Panel Discussion at Government COVID-19 Event
TORONTO, ON / ACCESSWIRE / January 20, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate. As part of a government and industry panel, Dr. Nijhawan is expected to discuss the importance of developing multiple countermeasures to the COVID-19 pandemic, including therapies, like Edesa s EB05 drug candidate, that target the overactive host immune response in COVID-19 patients.
Relief Therapeutics Holding AG: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
Relief ), a biopharmaceutical company with its lead compound RLF-100
TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH (
AdVita ), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases, today announced the companies have signed a binding term sheet for Relief to acquire all shares of AdVita in exchange for EUR 25 million of Relief common shares, plus possible future contingent milestone payments of up to EUR 20 million. The closing of the transaction is subject to customary closing conditions as well as legal and securities regulatory approvals and is expected to occur in Q2 2021.